Is This Embattled Pharma Stock Now a Buy?

2 | By Wall Street Insights and Indictments Staff

Ahead of congressional hearings to discuss the recent price boost for the company’s, EpiPen product, Shah speculated that pharmaceutical company Mylan NV (NASDAQ:MYL) could be a buy.

On the morning before the hearing, Shah said that the bad news was already out there, and as a result the stock was hovering just above its 52-week low. He further said that the stock was likely to bounce back – and he would even be looking to buy if it dipped lower during the hearings.

Sure enough, the stock has tacked on 4.74% since.

Shah also discussed Microsoft Corp. (NASDAQ:MSFT), Tesla Motors Inc. (NASDAQ:TSLA), the Bayer-Monsanto deal, December’s likely rate hike, and the politicization of the Fed.

Check out the full video below.

2 Responses to Is This Embattled Pharma Stock Now a Buy?

  1. Sonia Lee says:

    Dear Mr, GILANI, Thank you for your good advice.

    Yes, I would like someone like you to give a advice about my finance will

    coming -. I hope soon I will get it. Thanks.

Leave a Reply

Your email address will not be published. Required fields are marked *